Cipla Ltd
Tofacitinib (5mg)
Tofajak-IN 5mg Tablet is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Tablet
Tofajak-IN 5mg Tablet may be prescribed by itself or in combination with another medicine. The tablets can be taken with or without food and it is best to take them at the same time each day. Your dose will depend on your condition and what other medicines you are taking. You should use it as your doctor tells you to. Do not stop taking this medicine unless your doctor tells you to because your condition could get worse.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tofajak-IN 5mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Tofajak-IN 5mg Tablet is a Janus kinase inhibitor. It works by blocking the action of the enzyme Janus kinase. This decreases the activity of the immune system and inflammation associated with rheumatic diseases and ulcerative colitis.
Tofajak-IN 5mg Tablet can make it a bit harder for people to fight off infections. Inform your doctor if you have symptoms of an infection such as fever, chills, cough, and muscle aches. Your doctor may get TB (tuberculosis) skin test and a chest X-ray before starting treatment with this medication. Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.
You should inform your doctor about any pre-existing liver conditions before starting Tofajak-IN 5mg Tablet. This is because in some cases, Tofajak-IN 5mg Tablet may increase liver enzymes. Therefore, a liver function test should be conducted to evaluate the potential impact on your liver health and ensure safe treatment initiation. Although Tofajak-IN 5mg Tablet can be prescribed for patients with mild to moderate liver impairment, it is generally not advisable for those with severe liver impairment.
Tofajak-IN 5mg Tablet may potentially increase the risk of certain cancers (lymphoma and skin cancers) by affecting immune system function. If you have a history of cancer or are concerned about potential risks, it is crucial to inform your doctor.
Tofajak-IN 5mg Tablet is approved for use in individuals with moderate to severe rheumatoid arthritis. This condition affects the joints, and this medication is used when previous treatments have been ineffective or unsuitable for individual patients. Additionally, Tofajak-IN 5mg Tablet can be started earlier in treatment if a patient does not respond well to prescribed drugs.
It typically takes 2 to 8 weeks for Tofajak-IN 5mg Tablet to show significant improvements. However, it may take 3 to 6 months before you notice the full effects of this medication.
Before starting Tofajak-IN 5mg Tablet, or while taking it, blood tests are recommended to assess potential issues like low red blood cell count (anemia), low white blood cell count (neutropenia or lymphopenia), high blood fat (cholesterol), or elevated liver enzymes. These investigations ensure the medication's safe usage and minimize risks.
Tofajak-IN 5mg Tablet affects your immune system, potentially reducing your body's ability to fight off infections. This may increase the risk of serious or life-threatening infections, including tuberculosis. If an infection develops while taking this medication, it is crucial to seek prompt medical attention in a hospital setting.
It is not advisable to combine Tofajak-IN 5mg Tablet with tocilizumab. As both medicines impact the immune system, taking them together may further increase the risk of infection and potentially lead to complications.